KMDA
Price
$6.75
Change
+$0.15 (+2.27%)
Updated
Oct 16 closing price
Capitalization
376.37M
26 days until earnings call
Intraday Buy/Sell Signals
PAHC
Price
$38.57
Change
-$0.57 (-1.46%)
Updated
Oct 16 closing price
Capitalization
1.56B
19 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

KMDA vs PAHC

Header iconKMDA vs PAHC Comparison
Open Charts KMDA vs PAHCBanner chart's image
Kamada
Price$6.75
Change+$0.15 (+2.27%)
Volume$132.34K
Capitalization376.37M
Phibro Animal Health
Price$38.57
Change-$0.57 (-1.46%)
Volume$155.91K
Capitalization1.56B
KMDA vs PAHC Comparison Chart in %
KMDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PAHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KMDA vs. PAHC commentary
Oct 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KMDA is a Hold and PAHC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 17, 2025
Stock price -- (KMDA: $6.75 vs. PAHC: $38.57)
Brand notoriety: KMDA and PAHC are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: KMDA: 220% vs. PAHC: 49%
Market capitalization -- KMDA: $376.37M vs. PAHC: $1.56B
KMDA [@Pharmaceuticals: Generic] is valued at $376.37M. PAHC’s [@Pharmaceuticals: Generic] market capitalization is $1.56B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KMDA’s FA Score shows that 0 FA rating(s) are green whilePAHC’s FA Score has 1 green FA rating(s).

  • KMDA’s FA Score: 0 green, 5 red.
  • PAHC’s FA Score: 1 green, 4 red.
According to our system of comparison, PAHC is a better buy in the long-term than KMDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KMDA’s TA Score shows that 4 TA indicator(s) are bullish while PAHC’s TA Score has 2 bullish TA indicator(s).

  • KMDA’s TA Score: 4 bullish, 3 bearish.
  • PAHC’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, KMDA is a better buy in the short-term than PAHC.

Price Growth

KMDA (@Pharmaceuticals: Generic) experienced а -2.60% price change this week, while PAHC (@Pharmaceuticals: Generic) price change was +3.77% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.06%. For the same industry, the average monthly price growth was +6.77%, and the average quarterly price growth was +55.61%.

Reported Earning Dates

KMDA is expected to report earnings on Nov 12, 2025.

PAHC is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.06% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PAHC($1.56B) has a higher market cap than KMDA($376M). PAHC has higher P/E ratio than KMDA: PAHC (32.41) vs KMDA (21.09). PAHC YTD gains are higher at: 86.111 vs. KMDA (14.013). PAHC has higher annual earnings (EBITDA): 147M vs. KMDA (34.2M). PAHC has more cash in the bank: 77M vs. KMDA (66M). KMDA has less debt than PAHC: KMDA (11.4M) vs PAHC (762M). PAHC has higher revenues than KMDA: PAHC (1.3B) vs KMDA (170M).
KMDAPAHCKMDA / PAHC
Capitalization376M1.56B24%
EBITDA34.2M147M23%
Gain YTD14.01386.11116%
P/E Ratio21.0932.4165%
Revenue170M1.3B13%
Total Cash66M77M86%
Total Debt11.4M762M1%
FUNDAMENTALS RATINGS
KMDA vs PAHC: Fundamental Ratings
KMDA
PAHC
OUTLOOK RATING
1..100
7058
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
28
Undervalued
PROFIT vs RISK RATING
1..100
10036
SMR RATING
1..100
7949
PRICE GROWTH RATING
1..100
5440
P/E GROWTH RATING
1..100
47100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PAHC's Valuation (28) in the Pharmaceuticals Major industry is somewhat better than the same rating for KMDA (70) in the Biotechnology industry. This means that PAHC’s stock grew somewhat faster than KMDA’s over the last 12 months.

PAHC's Profit vs Risk Rating (36) in the Pharmaceuticals Major industry is somewhat better than the same rating for KMDA (100) in the Biotechnology industry. This means that PAHC’s stock grew somewhat faster than KMDA’s over the last 12 months.

PAHC's SMR Rating (49) in the Pharmaceuticals Major industry is in the same range as KMDA (79) in the Biotechnology industry. This means that PAHC’s stock grew similarly to KMDA’s over the last 12 months.

PAHC's Price Growth Rating (40) in the Pharmaceuticals Major industry is in the same range as KMDA (54) in the Biotechnology industry. This means that PAHC’s stock grew similarly to KMDA’s over the last 12 months.

KMDA's P/E Growth Rating (47) in the Biotechnology industry is somewhat better than the same rating for PAHC (100) in the Pharmaceuticals Major industry. This means that KMDA’s stock grew somewhat faster than PAHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KMDAPAHC
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
69%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
66%
Bullish Trend 4 days ago
74%
Momentum
ODDS (%)
Bearish Trend 4 days ago
66%
Bearish Trend 4 days ago
73%
MACD
ODDS (%)
Bullish Trend 4 days ago
65%
Bearish Trend 4 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
63%
Bullish Trend 4 days ago
70%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
66%
Bearish Trend 4 days ago
70%
Advances
ODDS (%)
Bullish Trend 9 days ago
64%
Bullish Trend 4 days ago
73%
Declines
ODDS (%)
Bearish Trend 11 days ago
65%
Bearish Trend 10 days ago
69%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
71%
N/A
Aroon
ODDS (%)
Bearish Trend 4 days ago
60%
Bearish Trend 4 days ago
68%
View a ticker or compare two or three
Interact to see
Advertisement
KMDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PAHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CBDYX57.29-0.13
-0.23%
Columbia Balanced Inst3
STCAX17.69-0.09
-0.51%
Virtus Silvant Large-Cap Growth Stk I
AGIZX89.24-0.56
-0.62%
Alger Growth & Income Z
PGRTX16.32-0.18
-1.09%
Principal SmallCap Growth I Instl
IEQAX16.87-0.22
-1.29%
ICON Equity Income Investor

KMDA and

Correlation & Price change

A.I.dvisor tells us that KMDA and SIGA have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KMDA and SIGA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KMDA
1D Price
Change %
KMDA100%
+2.27%
SIGA - KMDA
27%
Poorly correlated
-0.83%
OGI - KMDA
27%
Poorly correlated
-3.57%
SGIOY - KMDA
27%
Poorly correlated
-0.63%
CRDL - KMDA
25%
Poorly correlated
-3.70%
PAHC - KMDA
23%
Poorly correlated
-1.46%
More

PAHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, PAHC has been loosely correlated with AMRX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if PAHC jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PAHC
1D Price
Change %
PAHC100%
-1.46%
AMRX - PAHC
45%
Loosely correlated
+0.92%
ZTS - PAHC
42%
Loosely correlated
+0.80%
PBH - PAHC
41%
Loosely correlated
+1.44%
ELAN - PAHC
39%
Loosely correlated
+0.05%
VTRS - PAHC
37%
Loosely correlated
+1.20%
More